Biologics manufacturing is becoming increasingly complex. As new modalities emerge and patient populations become more targeted, manufacturers are under growing pressure to develop and produce therapies faster, more flexibly, and at lower cost. At the same time, advances in continuous bioprocessing, single-use technologies, and artificial intelligence are creating new opportunities to rethink how biologics are developed and manufactured.
In this conversation, Andy Lundeen speaks with Randal Bass, Executive Vice President, Process Design and Innovation at Just-Evotec Biologics, about the trends reshaping the bioprocessing industry. Their discussion explores the growing momentum behind continuous manufacturing, the maturation of single-use technologies, the practical applications of AI in biologics development and manufacturing, and how innovation may help expand patient access to biologic medicines.
This interview has been slightly edited for clarity from Randal Bass's appearance on the Pharma Manufacturing Podcast episode, "Adapting Biologics Manufacturing to a More Complex Market," hosted by Andy Lundeen. Listen to the original episode here.
Andy: Welcome to Off Script, a Pharma Manufacturing podcast. My name is Andy Lundeen, Senior Editor at Pharma Manufacturing, and today we'll be discussing how new technologies and manufacturing strategies are helping biopharma companies navigate the growing complexity of biologics development and production.
Joining me for today's conversation is Randal Bass, Executive Vice President of Process Design and Innovation at Just-Evotec Biologics, or JEB for short, a CDMO offering development and cGMP manufacturing services for antibody, next-generation biologics, and biosimilar products.
Welcome, Randal, and thanks for joining us today.
Randal: Thanks, Andy. Really appreciate the opportunity to talk to you today. This is a fun, exciting topic.
Andy: Yeah, great. Looking forward to it as well. Thank you so much.
To get started, the biologics pipeline continues to grow more complex, with increasingly specialized therapies. From your perspective as a CDMO, what is the state of the market today, and what are some of the biggest manufacturing challenges biopharma companies face as they bring these products to market?
Randal: Well, I think there are a couple of facets to it.
First and foremost, you're absolutely right that the landscape is getting more complex. There are fewer straight antibodies and far more complicated engineered therapies coming out.
The markets are also contracting. In the early part of my career, everybody was chasing billion-dollar blockbusters. Those are still present, but they're far fewer. So we're talking about more molecules coming into the pipeline, which is great because they're serving more therapeutic areas. But at the same time, the overall markets for each of those drugs are getting smaller. So you have a higher level of complexity and smaller markets.
What we've done, in addition to being a CDMO, is become what we call a CTDMO, where the "T" stands for technology. We've been heavily investing in technology in the biomanufacturing space for over a decade. We've created a series of platforms that enable exactly what we're talking about: more complex molecules, smaller market sizes, greater adaptability, and more flexibility. In fact, flexibility is a huge part of it.
One of the things we did from the start was focus on getting the fundamentals right. We talk about making sure molecules are engineered as well as possible, understanding the complexity of the molecules, whether they're bispecifics, Fc fusions, multispecifics, or fragments placed onto antibody backbones.
The more we can engineer the individual pieces correctly, and like many companies we've been using AI and machine-learning tools to improve that engineering, the easier it becomes to assemble those molecules.
The overall platform we've created is highly modular and highly intensified, but it's enabled by the fundamentals. We've engineered our cells to be better. We've engineered our vector systems to be better, delivering higher productivity and making it easier to assemble multispecific molecules. We've even created media that support highly intensified manufacturing and enable production for these smaller markets.
Again, it's a balance. Yes, the market is getting more complex, and yes, the individual markets are getting smaller. But that doesn't mean biopharma is getting smaller. Biopharma is actually getting bigger overall. The market shares on a per-therapeutic-area basis are becoming smaller and more fragmented.
That's a good thing because it means we're serving more patients across more diseases.
Andy: Yeah. Can you talk a little more about that trend toward market fragmentation? I was interested in exploring that further and how it has evolved.
Randal: A couple of things have happened.
Again, earlier in my career we talked about moving from murine antibodies to fully human antibodies. There were multiple billion-dollar blockbusters, actually multibillion-dollar blockbusters, and pharma relied heavily on those.
What's happened over the last 10 years, especially, is that many smaller companies have entered the market alongside the large biopharma players. They're bringing great ideas and investing in more complex biologics of all shapes and sizes, from small antibody fragments to multichain, multivalent molecules targeting a wide range of diseases.
At the same time, additional biomanufacturing centers have been built or expanded to support those markets.
One thing that's absolutely true is that biopharma has adjusted over the years to accommodate smaller market demands. You don't see many facilities with six, ten, or fifteen 20,000-liter stainless-steel reactors being built anymore. Instead, you're seeing smaller, more adaptable facilities centered around single-use systems.
The vendor community has responded as well. They've developed many more single-use technologies because that part of the market has grown significantly.
The blockbuster drugs are still going to be there, and we'll still use large stainless-steel facilities for them. But that's no longer the only route to market.
Today there are far more single-use systems supporting the industry, particularly 1,000-, 2,000-, and 3,000-liter single-use bioreactors.
Andy: I do want to pivot to single-use technologies because that's obviously a major part of this discussion. Just-Evotec Biologics has built its manufacturing platform around these technologies, as you alluded to earlier.
Can you talk about the significance of single-use technologies and some of the ways CDMOs are using them to rethink traditional manufacturing?
Randal: Well, they're finally getting good.
That's kind of a funny thing to say, but I've been working with single-use systems for a long time. We really started with bioreactors, but today essentially our entire biomanufacturing platform is built around single-use systems.
From the time we crack a vial until we fill drug substance, with a few notable exceptions, almost everything we do is single use.
We still pack our own columns, largely for cost reasons. Disposable columns are readily available now, and you can purchase them prepacked from multiple vendors, but essentially everything else is single use. The reason is that it massively simplifies your facility.
The challenge with large stainless-steel facilities is that they can contain miles of piping because everything has to be cleaned in place and sterilized in place. With single-use systems, facilities can be far less complex.
Listeners can't see this, but behind me is our J.POD® facility. It's about 135,000 square feet, which sounds large, but in our industry it's actually quite small. The last stainless-steel facility I worked in was around one million square feet.
Single-use systems enable a much smaller footprint. We perform a great deal of perfusion-based manufacturing, and all of our systems are intensified. Our downstream operations are highly efficient, with very high column loadings.
What this allows you to do is create a very small, simple facility that is much easier to operate. It requires fewer people. You don't need a massive natural gas-fired boiler generating all the steam required to clean and sterilize the facility. It's simply a much simpler approach.
Across the industry, whether companies are pursuing full end-to-end continuous manufacturing like we are or not, virtually everyone is using single-use systems. At a minimum they're often using single-use bioreactors because they streamline operations.
They make processes faster. They also significantly improve turnaround times. With fixed stainless-steel tanks, you have to clean and sterilize them before the next run. That consumes facility time.
With single-use systems, you can tear down and set back up in a fraction of that time.
Andy: You mentioned something earlier that I wanted to come back to. You said that single-use technologies are "finally getting good." I'm interested in where they were before and where they are now. Can you expand on what you mean by that?
Randal: Yeah. When we first started working with single-use systems, and this dates back to the mid-2000s when I got involved with them, to be honest, they weren't that great.
We didn't know how to do a lot of things, and it wasn't just one vendor. Pretty much everyone was figuring it out. A single-use bioreactor is essentially a glorified plastic bag that sits inside a metal vessel.
The challenge is how to use it in a way that keeps it sterile and intact. You still need to add material to it. Even in fed-batch processing, and back then we mostly did fed-batch whereas now we do continuous perfusion, you still have to open and close systems, sample them every day, and install pH and dissolved oxygen probes.
How do you do all of that without leaks and contamination? Well, it turns out we didn't always succeed. We had contaminations. Bags leaked. It was a real problem.
We also had film materials that were toxic. There were cases where bags actually poisoned cell cultures and cells wouldn't grow. We would stall out in the N-1 reactor. All of that happened.
What changed is that the industry learned. We partnered with suppliers and vendors, and everything improved. Single-use connectors improved. Film materials improved. Port systems improved. Probe interfaces improved. Everything improved. Today, we still see some of the same issues, but they're much less frequent.
Another major improvement is diversification of the supply chain. We now have more vendors providing these technologies. As industries mature, supply chains become stronger, and we've benefited from that.
At the same time, the equipment itself has improved. The skids we use have gotten significantly better.
We still see a lot of innovation in the space. We actually partner with some of the major vendors because we can serve as a proving ground for new technologies, and they're investing heavily in single-use systems, advanced manufacturing, and continuous manufacturing alongside us.
Andy: Do you mind expanding on what you mentioned about the skids improving and what that progression has looked like?
Randal: Sure.
One useful example is continuous manufacturing because it really represents the full advanced biomanufacturing package that many people are trying to achieve.
We've worked closely with groups like the FDA Emerging Technology Team. There is significant interest from government agencies in advancing U.S. biomanufacturing.
We've also partnered with major industry vendors in this space. One of the key enablers is the equipment itself.
In some cases, we've built elements ourselves. For example, we developed our own SCADA layer, meaning Supervisory Control and Data Acquisition, which is essentially the central intelligence coordinating everything.
If you're operating a fully continuous process, you need a supervisory control system that orchestrates all the operations and ensures the automation works together.
At the individual skid level, however, we're vendor agnostic. We want the best equipment available.
If someone develops a better bioreactor, that's great. We'll connect it to our SCADA system. If another company develops a better chromatography skid, that's great too.
When we originally built our platform, however, there were several pieces of equipment we simply couldn't buy. They didn't exist. We had to custom-build them ourselves.
Frankly, I'd much rather purchase those systems off the shelf because then we aren't investing resources into building them. More importantly, we can rely on support from major suppliers like Cytiva, Sartorius, Pall, and Repligen.
Over the last several years we've seen substantial investment in continuous and advanced manufacturing. The major vendors are investing heavily, which is fantastic.
Take viral inactivation, for example. Viral inactivation is something we perform on virtually every biologic product. Traditionally, you place material into a tank, lower the pH, hold it for a specified period, and then bring the pH back up. We've been doing that for decades.
Today, some vendors have developed compact continuous-flow reactor systems that can accomplish the same task in a fraction of the footprint. They're simpler and potentially more robust.
That's exactly the kind of innovation we're looking for. Show us a validated skid using fully disposable consumables and we'll absolutely consider integrating it.
Sartorius, for example, now has nearly an entire equipment line that has been designed around continuous manufacturing principles, and they're continuing to invest in it.
What has really changed is that continuous manufacturing is no longer theoretical. We've recently seen public examples of adoption. One well-known example is that Sandoz licensed our technology and acquired the facility we built in Toulouse.
What was important about that wasn't just the transaction itself. It demonstrated that one of the world's largest biosimilars companies was actively investing in advanced manufacturing. That got people's attention across the industry. It validated the concept.
This isn't something that's discussed only at integrated continuous biomanufacturing conferences anymore. It's real. These manufacturing platforms work.
They're not the answer for every molecule, but they can provide a significant advantage when applied to the right products in the right circumstances. That's really what's changed.
Andy: Sticking with the single-use discussion, but looking at it from a different angle, I was reading one of your recent announcements and noticed the platform was described as a "mostly single-use" design.
What does that mean in practice? I know you're not running massive stainless-steel bioreactors, so I'm not really thinking about a hybrid manufacturing model. I'm curious where the remaining non-single-use elements fit into the overall approach.
Randal: For us, there are only a few things that aren't single use.
One example is that we still pack our own columns. But even that isn't really necessary anymore. The reason we continue to do it is cost.
The reality is that biologic drugs are incredible. I've spent more than 20 years working on them. They're remarkable therapies. They treat cancer, address severe diseases, and help people regain quality of life. But the reality is that most of the world still can't afford them.
One of the reasons we created this company was to help address that issue. Single-use systems actually contribute to that objective.
It may sound counterintuitive, but these systems can lower costs and reduce overall carbon footprint. Large stainless-steel facilities require enormous amounts of steam, caustic chemicals, infrastructure, labor, and operational complexity.
We've moved almost everything apart from a few areas, including column packing, into fully disposable systems because they help reduce manufacturing costs.
As competition increases in the single-use column market, we'll likely continue moving further in that direction. For example, we were intentionally positioned to adopt prepacked Protein A columns as soon as the economics make sense.
In traditional fed-batch manufacturing, large-scale operations often required very large chromatography columns. Protein A resin is one of the most expensive components we use.
In our continuous process, however, we operate with very small columns on multicolumn chromatography systems. We essentially utilize the full lifetime of those columns within a single manufacturing campaign. Functionally, that behaves much more like a single-use approach.
As vendors continue improving offerings and lowering costs, we'll adopt those systems as well. That may sound wasteful at first glance, but when you look at total cost and overall carbon footprint, the data suggest it can actually be the better approach.
Andy: And just to pivot a bit, moving from process development to commercial production remains a major challenge in biologics manufacturing. How can an integrated development and manufacturing strategy help reduce scale-up risk, particularly given the increasingly complex biologics landscape?
Randal: Yeah. I think one of the things I've been really fortunate to experience throughout my career is having development labs located immediately adjacent to manufacturing facilities.
That sounds simple, but it turns out that the flow of information between the manufacturing floor and the development labs is incredibly important.
At the same time, we've developed much better analytical capabilities. Frankly, the analytical tools available today are far better than they were when I started my career. The capabilities that many companies now deploy are extremely strong.
What that allows us to do is not only build scale-down models but also connect those models to sophisticated analytical packages that are absolutely required for today's more complex biologics.
You need to understand how components are paired together. You need to understand impurity profiles, partial molecules, degradation products, and all the attributes that these increasingly complex molecules are susceptible to.
By doing that, we can create better scale-down models that are more predictive of scale-up risk. As we move from our Amber 250 perfusion systems, or from our 3-liter perfusion-capable bench-scale bioreactors, into larger scales, we use those as benchmark models.
We also operate a pilot facility at the 50-liter scale. That may sound small, but productivity levels have increased so much that we can actually generate early clinical material even at that scale.
The broader point is that we simply don't need to get very large anymore. Our production reactors operate at peak volumes of only 500 and 1,000 liters. Because the jump from bench scale to pilot scale to commercial scale is relatively modest, the scale-up risk is dramatically reduced.
When you're scaling from a 3-liter bench reactor to a 20,000-liter commercial reactor, that's a significant challenge. Scale risk exists throughout the process.
You suddenly have very large chromatography columns, larger fluid movements, greater shear exposure, and many other factors that can affect product quality.
With our approach, we've intentionally scaled things down and intensified processes in a way that minimizes those risks.
I think many companies across the industry recognize that and are increasingly adopting single-use bioreactors and perfusion technologies because they help reduce scale-up risk as much as possible.
Andy: Sure. When you mentioned earlier the improvements in analytical capabilities, I couldn't help but think about AI and how it's impacting the space.
Is AI really a key part of this broader analytical improvement story that's happening right now?
Randal: Yes, very much so.
In fact, I'm currently pushing to get permission to turn an AI agent loose inside our electronic laboratory notebook.
One of the advantages of starting a new company is that you get to design everything from scratch. From the beginning, we created a structured database integrated directly with our electronic lab notebook. That allows us to do things that are much harder for organizations dealing with multiple disconnected databases and large amounts of unstructured data.
We actually started by using machine-learning tools. It's important to note that we have a dedicated Data Sciences Group, and frankly most successful biopharma companies now employ data scientists in one form or another.
I once went to our data scientists with what I thought was a very reasonable request. I said, "I've got all this data. We've been using automated RoboColumns on robotic systems, and they've generated thousands of data points. Can you build me a data-visualization tool?"
They kind of patted me on the head and said, "That's cute, Randal, but what if we just build a six-variable polynomial model and tell you exactly how to operate it?" That was a great example of how much more advanced these capabilities have become.
We've built a very data-rich environment. We've implemented more analytical tools than ever before, and we've structured the underlying database in a way that allows machine-learning and AI systems to operate effectively.
Initially we used machine-learning approaches, and now we're beginning to apply AI tools to the same datasets.
The goal is to determine whether we can leverage all of the information we've generated across multiple programs and focus experimental development efforts more efficiently.
As biologics become more complex, the associated analytical profiles also become more complicated. These tools can help us better understand those molecules and direct development resources where they will be most effective.
It's actually a very exciting time. I've spoken about this at conferences, and what we're seeing are genuine advances, not just hype. These aren't theoretical concepts. They're real tools that can actually help us.
To be clear from a GMP perspective, we are not using these systems for autonomous decision-making. However, we are absolutely analyzing data offline and asking practical questions.
For example, can we use machine-learning models to predict when a Protein A column is going to fail? Protein A columns have finite lifetimes.
Can we combine first principles of chromatography, half-height measurements, elution traces, conductivity profiles, cleaning histories, and cycle data to predict remaining useful life? The answer appears to be yes.
We can build models that estimate a column may fail in two or three additional cycles. That's incredibly valuable because it allows us to avoid failures by proactively replacing columns or adjusting operations. Those are practical applications delivering real value.
The same is true for AI. My original training is as an X-ray crystallographer and structural biologist. For years, predicting protein structures was one of the major challenges in biology. Today, AI tools have become extremely good at that task.
You can provide a ligand and potentially identify candidate antibody CDR domains that can be engineered around it.
When you're building complex molecules, such as multispecific biologics made from multiple antibody fragments, these tools become incredibly useful.
We also possess extensive libraries of antibody variants and antibody-like fragments that we've generated over the years. That creates a rich training dataset.
We're increasingly able to turn AI systems loose on those datasets and ask: "What have we actually learned from the molecules we've already built?"
That should help us design better molecules from the very beginning.
Andy: Right. Yeah. That's great. Thanks for explaining that. It's really exciting.
I'd like to pivot back to continuous bioprocessing and focus specifically on the barriers that have limited broader adoption.
Do you think we're reaching a tipping point for wider adoption of continuous bioprocessing?
Randal: I do.
And that's a great question because continuous bioprocessing is hard. Frankly, it's taken the industry a long time to get here. From the earliest days of single-use systems and continuous manufacturing concepts, we've been working toward this.
Even looking at standards, ICH Q13 has only been available for a few years. It took the industry a long time to reach the point where we could even produce a guidance document that clearly defined what continuous manufacturing means.
It's also taken time for regulatory agencies to build experience and confidence.
I have a lot of respect for the FDA Emerging Technology Team. We've worked closely with them, and the back-and-forth interaction between regulators and industry has been essential.
The FDA can't do it without industry, and industry can't do it without the FDA. That iterative dialogue has been very important.
The same is true for conferences such as Integrated Continuous Biomanufacturing (ICB), where regulators, manufacturers, technology developers, and service providers can interact directly.
It has taken time to build consensus, but we're getting there. At the same time, we've seen tremendous growth in industry investment.
We're in a somewhat unique position because of our continuous-manufacturing focus, and we interact with companies across the industry. I can tell you there is significant interest.
There is far more investment than I've seen at any point in my career. At the last ICB conference, attendance demand was so high there was a substantial waiting list. I fully expect the next conference to be the same.
One of my colleagues, Eva Gefroh, is actually involved in organizing the event, and there's already a lot of enthusiasm around it. Participation spans the industry. Virtually every major biopharma company is represented. Beyond conferences, we see it in our day-to-day interactions.
Companies are investing in intensified and continuous manufacturing platforms. There are better systems available. There are more vendors. Supply chains have matured. Regulatory understanding has improved.
And perhaps most importantly, products are now moving into late-stage and commercial manufacturing using these approaches.
That puts a stamp of legitimacy on the technology. You can feel the industry reaching a tipping point.
And if we come back to where we started, market fragmentation is one of the forces driving this transition. More patients are being treated across more diseases, but the individual markets are smaller.
That is precisely where intensified manufacturing, adaptable facilities, and smaller single-use systems create value. I think those trends are beginning to converge.
Now, large stainless-steel facilities will absolutely continue to have a role. I grew up professionally working in those facilities, and they are incredible feats of engineering. When they're fully utilized, they're remarkably efficient. But they won't necessarily be the best answer for every molecule going forward.
Andy: Right. I wanted to touch a little bit on the conversations you mentioned having with the FDA and the importance of that communication, especially when we think about some of the broader geopolitical factors we're seeing today, including the push toward reshoring and supply-chain resilience.
Why is that communication so important right now?
Randal: I think the U.S. federal government has done a good job recognizing that biopharmaceutical manufacturing is an area where the United States has real strengths.
Biopharma has been a successful industry for the country. We're leveraging innovation, and we benefit from a large R&D network that helps train and supply talented scientists and engineers. That's been enabled, in part, by longstanding federal investment.
The government has also made specific efforts to encourage innovation. The FDA's Emerging Technology Team is a great example. Their message has been very clear: we want innovation in this space.
The U.S. has traditionally been strong in biopharmaceutical innovation, and while I sometimes hear colleagues joke that we're a dinosaur because we move slowly, the FDA has actually been very supportive of innovation.
We also have organizations like the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), which exists specifically to advance manufacturing technologies.
NIIMBL provides pilot-scale spaces for development work and actively seeks partnerships with industry. That's an area where we've definitely felt support from the federal government.
Other parts of the federal government have also invested in biomanufacturing. The Department of Defence has invested in medical countermeasures and biomanufacturing capabilities. Likewise, BARDA has invested in the space, which is a good thing for the country.
Now, we're operating in an environment where there is increasing emphasis on onshoring and nearshoring because of geopolitical realities.
As a country, we're actually well positioned to absorb some of that demand. You can feel the expansion taking place. Capacity is growing in the United States to support nearshoring and onshoring efforts.
But the important point is that technology investment matters just as much as capacity investment. It's not simply about building more facilities or installing more bioreactors. It's about investing in the technologies that allow us to manufacture better, more efficiently, and more flexibly.
If we do that correctly, we can absorb even more manufacturing domestically. It's really a win-win. We can strengthen supply-chain resilience, maintain a safe drug supply, and support smaller and more specialized markets.
At the same time, we should continue investing in technologies that reduce manufacturing costs. The more we lower the cost of producing biologic medicines, the more patients can access them and the more markets can be served.
That doesn't have to be a negative outcome economically. In fact, it can open new markets and help expand the industry overall.
Andy: Great. Awesome.
There are obviously newer manufacturing approaches, including the platform your team has developed, that are helping support increasingly complex biologics.
What other advances in process development and manufacturing are expanding what's possible for these more challenging molecules?
Randal: I think one of the things that's really encouraging is that the fundamental tools we have available today continue to improve.
We've been able to take advantage of advancements from the last 10 to 15 years and incorporate them into biologics development. Take something like CRISPR, for example. Can you use CRISPR to engineer better cell lines? Absolutely. That's one example of how focusing on the fundamentals can create meaningful improvements.
It takes time to engineer cells. It takes time to optimize glycan profiles. It takes time to build better vector systems that support higher specific productivity.
But those investments become even more important as molecules become more complex.
When you're working with what I jokingly call "Frankenbodies," highly engineered and highly complex biologics, they become much harder to manufacture.
They don't always fold as efficiently. Cells don't always process them as easily.
But if you've invested the effort to improve the fundamental biology, those cells become far better equipped to produce both conventional monoclonal antibodies and far more complex biologics.
One of the things we've demonstrated is that continuous manufacturing can provide additional advantages as molecule complexity increases.
A bioreactor is actually one of the least desirable places for a finished protein molecule to spend time. The temperature is ideal for enzyme activity. There are cofactors present. There are media components present. There are multiple opportunities for modifications or degradation.
The faster you can move a molecule out of the bioreactor and into its most stable state, the better. For many complex biologics, stability becomes a real challenge.
You can see clipping liabilities. You can see unwanted post-translational modifications. You can see degradation pathways that become increasingly important as molecular complexity increases.
The sooner you can get that molecule into purified, formulated drug substance, the better off you are.
So it really starts with fundamentals. Build cells that can make the molecule efficiently, then build downstream processes that can purify it quickly and move it into a stable formulation as rapidly as possible.
Andy: Great. Awesome.
I have one final forward-looking question.
Looking ahead, how do you see biologics manufacturing evolving in the coming years, and what technologies or trends do you think will have the biggest impact?
Randal: One thing I really like seeing is the increasing investment from technology providers and equipment vendors. The single-use systems continue to improve. Skid designs continue to improve. We have more tools available than ever before.
For example, we're currently using technologies like single-pass tangential-flow filtration and inline diafiltration to support continuous formulation processes. Those systems are already impressive.
But we're also seeing new approaches emerge. Recently there's been interesting work around counter current dialysis systems that are elegant, compact, and potentially very effective. If those become commercially available, I'd be thrilled to adopt them.
We're also going to continue seeing broader adoption of advanced manufacturing approaches. Protein biologics remain a very large part of the industry, but we're also seeing expansion in cell therapies and gene therapies.
Many of the manufacturing concepts currently being advanced within protein biologics will eventually migrate into those fields as well.
For example, viral-vector production and purification workflows are increasingly likely to adopt single-use platforms and greater automation. In many ways, protein biologics are serving as a proving ground.
We are helping establish manufacturing approaches, qualification strategies, validation frameworks, and GMP-compatible operating models that can later be applied across other therapeutic modalities.
I have no doubt we'll see continued adoption of single-use systems and increased automation throughout those sectors.
The other thing I'd like to see is continued collaboration across the industry. Organizations like NIIMBL, industry conferences, and broader industry consortia create opportunities for manufacturers, suppliers, regulators, and developers to learn from one another.
I actually think our industry has improved significantly in that regard. We're doing a better job of collaborating, sharing lessons learned, and collectively addressing challenges associated with advanced biomanufacturing.
Personally, I'm always looking for opportunities to partner with others in the industry and discuss these topics. Ultimately, success in this area is shared success.
The more effectively we collaborate, the more progress we'll make together.
Andy: Thank you for listening to this episode of Off Script, a Pharma Manufacturing podcast produced by Endeavor Business Media, a division of Endeavor Business Media.
Be sure to subscribe or follow in your favorite podcast app so new episodes are delivered directly to you.
For more insights, visit pharmamanufacturing.com and follow the publication on Facebook, LinkedIn, and X.
Until your next listen, have a great day.
Source & Copyright
This interview has been edited for clarity from Randal Bass's appearance on the Pharma Manufacturing podcast episode, "Adapting Biologics Manufacturing to a More Complex Market." The original conversation was hosted by Andy Lundeen.
Edited and reproduced with permission from Pharma Manufacturing, an Endeavor Business Media publication. Original podcast episode copyright © Pharma Manufacturing.